MedTrace Logo

Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism

NCT04126941 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2019-10-15

No results posted yet for this study

Summary

Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk of long term hypercalciuria, nephrocalcinosis and further renal impairment. The use of teriparatide has been reported in adults (daily or bi-daily subcutaneous infusions) and in children (rather continuous subcutaneous infusion) as second-line therapy.

The objective of this study is to obtain efficacy and safety data on the use of teriparatide in children with hypoparathyroidism to improve our knowledge of their management.

Conditions

  • Hypoparathyroidism

Interventions

OTHER

Serum calcium concentrations results

To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04126941 on ClinicalTrials.gov